Article
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis.
Clinical pharmacology and therapeutics - 1 Mar 2011
Herrlinger K R, Koc H, Winter S, Teml A, Stange E F, Fellermann K, Fritz P, Schwab M, Schaeffeler E
Abstract excerpt
Tacrolimus (Tac) is effective in the treatment of steroid-refractory ulcerative colitis (UC); however, nonresponse and unpredictable side effects are major limitations. Because Tac response in patients who have undergone solid-organ transplantation has been associated with the presence of variants in CYP3A and ABCB1, we elucidated the contributions of CYP3A4*1B and CYP3A5*3 and of ABCB1 1236C>T, 2677G>T,A, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
